The incidence and prevalence of anemia increase with age. Anemia of chronic disease is the most common form of anemia in the elderly. Distinguish two main groups of anemia of chronic disease: type of rheumatoid arthritis and neoplastic type. In the development of the anemia of chronic disease involved various independent mechanisms. The most well studied mechanism of iron sequestration. Inhibition of erythropoietin production, inhibition of erythroid precursors in the bone marrow and reduced life expectancy of erythrocytes plays an active role in the development of anemia. Iron deficiency is mainly due to chronic blood loss from ulcers, cancer, diverticula, or angiodysplasia. Hepcidin is the central regulator of systemic iron homeostasis. Knockout mice gepsidin production leads to development of hemochromatosis with multiorgan iron overload. Оn the contrary, transgenic mice overexpressing gepsidin die from iron deficiency anemia. Vitamin B12 deficiency should be suspected in all elderly patients with decreased levels of cobalamin below 300 pg / ml. Most frequently this is due to malabsorption of vitamin B12 due to increased gastric pH and reduce the production of pepsin. In the older population, the diagnosis of anemia may be delayed by a number of age-related conditions.
1. Ania B.J., Suman V.J., Fairbanks V.F., et al. Incidence of anemia in older people: an epidemiologic study in a well defined population // J. Am. Geriatr. Soc. . 1997. . Vol. 45. . P. 825-831.
2. Schrijvers D., Highley M., De Bruyn E., et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents // Anticancer Drugs. . 1999. . V. 10. . P. 147-153.
3. Gabrilove J. Overview: erythropoiesis, anemia, and the impact of erythropoietin // Semin. Hematol. . 2000. . V. 37. . Suppl. 6. . P. 1-3.
4. Zauber N.P., Zauber A.G. Hematologic data of healthy very old people // JAMA. . 1987. . V.257. . P. 2181-2184.
5. Inelmen E.M., Alessio M.D., Gatto M.A., et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people at home: some results of an Italian multicentric study // Aging. . 1994. . V. 6. . P. 81-89.
6. Quaglino D., Ginaldi L., Furia N., et al. The effect of age on hemostasis // Aging (Milano). . 1996. . V. 8. . P. 1-12.
7. Smith D.L. Anemia in the elderly // Am. Fam. Physician. . 2000. V. 62. . P. 1565-1572.
8. Balducci L. Anemia, cancer and aging // Cancer Control. - 2003. - V. 10. . P. 478-486
9. Ania B.J., Suman V.J., Fairbanks V.F., et al. Prevalence of anemia in medical practice: community versus referral patients // Mayo. Clin. Proc. . 1994. - V. 69. . P. 730-735.
10. Krantz S.B. Pathogenesis and treatment of the anemia of chronic disease // Am. J. Med. Sci. . 1994. . V. 307. . P. 353-359.
11.Cleeland C.S., Demetri G.D., Glaspy J., et al. Identifying hemoglobin levels for optimal quality of life: results of an incremental analysis // Proc. Annu. Meet. Am. Soc. Clin. Oncol. . 1999. . V. 18. . P. 2215.
12. Daly M.P. Anemia in the elderly // Am. Fam. Physician. . 1989. . V. 39. . P. 129-136.
13. Majdpour C., Spahn D.R., Weiskopf R.B. Anemia and perioperative red blood cell transfusion: a matter of tolerance // Crit. Care. Med. . 2006. . V. 34. . Suppl. . P. S102-S108.
14. Hebert P.C., Van der Linden P., Biro G., et al. Physiologic aspects of anemia // Crit. Care. Clin. . 2004. . V. 20. . P. 187-212.
15. Thomas D. The physiology of oxygen delivery // Vox Sang. - 2004. . V. 87. . Suppl. 1. .P. 70-3.
16. Ick B.E., Rigolet M., Van Der Linden P.J. Cardiovascular and metabolic response to acute normovolemic anemia. Effects of anesthesia // Anesthesiology. . 2000. . V. 93. . P. 1011-1016.
17. Van der Linden P., De Hert S., Mathieu N., et al. Tolerance to acute isovolemic hemodilution. Effect of anesthetic depth // Anesthesiology. . 2003. . V. 99. . P. 97-104.
18. Bowens C. Jr., Spahn D.R., Frasco P.E., et al. Hemodilution induces stable changes in global cardiovascular and regional myocardial function // Anesth. Analg. . 1993. . V. 76. . P. 1027- 1032.
19. Weiskopf R.B., Viele M.K., Feiner J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia // JAMA. . 1998. . V. 279. . P. 217-221.
20. Zarychanski R., Houston D.S. Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response // CMAJ. . 2008. . V. 179. . P. 333-337.
21.Gledhill N., Warburton D., Jamnik V. Haemoglobin, blood volume, cardiac function, and aerobic power // Can. J. Appl. Physiol. . 1999. . V. 24. . P. 54-65.
22. Volkova N., Arab L. Evidence-based systematic literature review of hemoglobin/ hematocrit and all-cause mortality in dialysis patients // Am. J. Kidney. Dis. . 2006. . V. 47. . P. 24-36.
23. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure // Am. Heart. J. . 2005. . V. 149. . P. 391-401.
24. Caro J.J., Salas M., Ward A., et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review // Cancer. . 2001. . V. 91. . P.2214- 2221.
25. Bolger A.P., Doehner D., Sharma R. Anaemia in chronic heart failure: the relationship to inflammatory cytokine expression and prognostic importance // Circulation. . 2002. . V.106. . P. S570-S571.
26. Kosiborod M., Curtis J.P., Wang Y., et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project // Arch. Intern. Med. . 2005. . V. 165. . P. 2237-2244.
27.Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review // Scand. J. Clin. Lab. Invest. . 2000. . V.60. . P. 259-273.
28. Mazess RB. Biological adaptation: aptitudes and acclimatization. In: Watts ES, Johnston FE, Lasker GW, editors. Biosocial interrelations in population adaptation. The Hague: Mouton; -2008. . P. 9-18.
29. Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasia // Life Sci. . 1992. . V.50. . P. 1289-1297.
30. Afzali B., Goldsmith D.J. Intravenous iron therapy in renal failure: Friend and foe // J. Nephrol. . 2004. . V.17. . P. 487-495.
31. Zurlo M.G., De S.P., Borgna-Pignatti C., et al. Survival and causes of death in thalassaemia major // Lancet. . 1989. . V.2. . P. 27-30.
32. Tong E.M., Nissenson A.R. Erythropoietin and anemia // Semin. Nephrol. . 2001. . V. 21. . P. 190-203.
33. Chronic Kidney Disease. In: Healthy People 2010. Vol 1.Objectives for Improving Health. Part A: Focus Areas 1-14. US Dept of Health and Human Services - 2000.
34. Chiari M.M., Bagnoli R., De Luca P., et al. Influence of acute inflammation on iron and nutritional status indexes in older inpatients // J. Am. Geriatr. Soc. . 1995. . V. 43. . P. 767-771.
35. Abramson S.D., Abramson N. gCommonh uncommon anemias // Am. Fam. Physician. . 1999. . V. 59. . P.851-858.
36. Nemeth E., Ganz T. The role of hepcidin in iron metabolism // Acta Haematol. . 2009. . V. 122. . P. 78.86.
37. Viatte L., Lesbordes-Brion J.C., Lou D.Q., et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice // Blood. . 2005. . V. 105. . P. 4861.4864.
38. Nicolas G., Bennoun M., Porteu A., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin // Proc. Natl. Acad. Sci. U S A. . 2002. . V. 99. . P. 4596.4601.
39. Papanikolaou G, Tzilianos M, Christakis JI., et al. Hepcidin in iron overload disorders // Blood. . 2005. . V. 105. . P. 4103.4105.
40. Young B., Zaritsky J. Hepcidin for Clinicians // Clin. J. Am. Soc. Nephrol. . 2009. . V. 4. . P. 1384.1387.
41.Valore E.V., Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin // Blood. Cells. Mol. Dis. . 2008. . V. 40. . P. 132.138.
42. Donovan A., Lima C.A., Pinkus J.L., et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis // Cell. Metab. . 2005. . V. 1. . P. 191.200.
43. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly // Arch. Intern. Med. . 1996. . V. 156. . P. 1097-1100.
44. Sumner A.E., Chin M.M., Abrahm J.L., et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery // Ann. Intern. Med. . 1996. . V.124. . P. 469-476.
45. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender // J. Lab. Clin. Med. . 1995. . V.126. . P. 57-64.
46. Nafziger J., Pailla K., Luciani L., et al. Decreased erythropoietin responsiveness to iron deficiency anemia in the elderly // Am. J. Hematol. . 1993. . V.43. . P.172-176.
47. Ahluwalia N., Lammi-Keefe C.J., Bendel R.B., et al. Iron deficiency and anemia of chronic disease in elderly women: a discriminate-analysis approach for differentiation // Am. J. Clin. Nutr. . 1995. . V.61. . P. 590-596.
48. Glaspy J., Bukowski R., Steinberg D., et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group // J. Clin. Oncol. . 1997. . V.15. . P. 1218-1234.
49. Demetri G.D., Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group // J. Clin. Oncol. . 1998. . V. 16. . P. 3412-3425.
50. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial // J. Clin. Oncol. . 2001. . V. 19. . P. 2865- 2874.